The price of Telesis Bio Inc (NASDAQ:TBIO) shares last traded on Wall Street fell -4.36% to $0.38.
Based on available information, 1 analysts follow Telesis Bio Inc (NASDAQ:TBIO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $4.00 and a low of $4.00, we find $4.00. Given the previous closing price of $0.40, this indicates a potential upside of 900.0 percent. TBIO stock price is now -55.78% away from the 50-day moving average and -76.72% away from the 200-day moving average. The market capitalization of the company currently stands at $11.47M.
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $4.00 as their price target over the next twelve months.
In other news, Nelson Todd Robert, President & CEO sold 2,575 shares of the company’s stock on May 04. The stock was sold for $7,277 at an average price of $2.83. Upon completion of the transaction, the President & CEO now directly owns 136,072 shares in the company, valued at $51707.36. An SEC document containing details of the transaction can be found on the SEC’s website. On May 04, Chief Technology Officer Gibson Daniel Glenn sold 1,190 shares of the business’s stock. A total of $3,363 was realized by selling the stock at an average price of $2.83. This leaves the insider owning 102,083 shares of the company worth $38791.54. Insiders disposed of 4,939 shares of company stock worth roughly $1876.82 over the past 1 year. A total of 70.78% of the company’s stock is owned by insiders.
A candlestick chart of Telesis Bio Inc (NASDAQ: TBIO) showed a price of $0.5073 on Friday morning. During the past 12 months, Telesis Bio Inc has had a low of $0.30 and a high of $3.32. As of last week, the company has a debt-to-equity ratio of 1.07, a current ratio of 2.07, and a quick ratio of 1.91. The fifty day moving average price for TBIO is $0.8473 and a two-hundred day moving average price translates $1.6356 for the stock.
The latest earnings results from Telesis Bio Inc (NASDAQ: TBIO) was released for Sep, 2023. According to the Medical Devices Company, earnings per share came in at -$0.37, missing analysts’ expectations of -$0.3 by -0.07. This compares to -$0.42 EPS in the same period last year. The net profit margin was -129.63% and return on equity was -76.49% for TBIO. The company reported revenue of $5.56 million for the quarter, compared to $6.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -16.64 percent. For the current quarter, analysts expect TBIO to generate $9.5M in revenue.
Telesis Bio Inc(TBIO) Company Profile
Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system, including BioXp 3250 system, BioXp 9600 system, and BioXp DBC, which are empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits, such as BioXp De Novo kits, BioXp select kits, BioXp next generation sequencing kits, and BioXp DBC kits, which contains building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and short oligo ligation assembly enzymatic DNA synthesis designs to significantly reduce timelines for constructing synthetic DNA, RNA, and proteins compared to traditional chemical synthesis, paving the way for more efficient and effective development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
